GlassScriptPhysician profile
Charles Kistler
NPI 1083750673
$7,031.83
in general payments reported to CMS, 2019-2025
43 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,830 · 2020: $2,106 · 2021: $2,083 · 2023: $12.97.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $12.97.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $12.97 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,345.75 | 2019-2021 | |
| Allergan, INC. | $579.16 | 2019-2020 | |
| Novartis Pharmaceuticals Corporation | $541.09 | 2019-2021 | |
| Sunovion Pharmaceuticals INC. | $276.89 | 2019-2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $275.71 | 2019-2021 | |
| Merck Sharp & Dohme LLC | $268.31 | 2019-2021 | |
| Pfizer INC. | $251.88 | 2019-2020 | |
| Biohaven Pharmaceuticals, INC. | $243.87 | 2020-2021 | |
| Neurocrine Biosciences, INC. | $238.72 | 2019-2021 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $234.89 | 2019-2021 | |
| Amgen INC. | $232.83 | 2019-2021 | |
| Novo Nordisk INC | $227.54 | 2019-2021 | |
| Janssen Pharmaceuticals, INC | $226.67 | 2019-2021 | |
| Abbvie INC. | $216.28 | 2020-2021 | |
| Glaxosmithkline, LLC. | $193.11 | 2019-2020 |
Show all 43 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Charles Kistler listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.